Perceptive Advisors’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Perceptive Advisors’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-500,000	Closed	-$3.65M	–	110
2022 Q4	$3.65M	Hold	500,000	–	–	0.1%	78
2022 Q3	$3.87M	Sell	500,000 -573,995	-53%	-$4.87M	0.11%	89
2022 Q2	$7.31M	Sell	1,073,995 -120,000	-10%	-$918K	0.23%	72
2022 Q1	$9.52M	Hold	1,193,995	–	–	0.19%	85
2021 Q4	$6.69M	Sell	1,193,995 -48,884	-4%	-$367K	0.1%	109
2021 Q3	$9.56M	Sell	1,242,879 -257,121	-17%	-$2.35M	0.14%	105
2021 Q2	$15.4M	Hold	1,500,000	–	–	0.2%	93
2021 Q1	$15.8M	Hold	1,500,000	–	–	0.2%	90
2020 Q4	$20.9M	Hold	1,500,000	–	–	0.22%	82
2020 Q3	$21.6M	Buy	+1,500,000	New	+$20.5M	0.31%	65

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Perceptive Advisors's PNT Position: Q1 2023 in Review

Perceptive Advisors sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q1 2023, closing a stake of 500,000 shares — an estimated $3.65M sold.

Perceptive Advisors first reported a position in PNT in Q3 2020 and held it in 10 quarters. The position peaked at $21.6M in Q3 2020. 115 funds tracked by Wall St. Rank hold PNT as of Q1 2023.

Perceptive Advisors reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Perceptive Advisors sold 500,000 POINT Biopharma Global Inc. Common Stock shares in Q1 2023, an estimated $3.65M.
Perceptive Advisors first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2020 and held it in 10 quarters.
Perceptive Advisors's POINT Biopharma Global Inc. Common Stock position peaked at $21.6M in Q3 2020.
115 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q1 2023.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.